Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2018 - 2025)

China SXT Pharmaceuticals has reported Accumulated Expenses over the past 8 years, most recently at $275004.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 111.63% year-over-year to $275004.0; the TTM value through Sep 2025 reached $275004.0, up 111.63%, while the annual FY2025 figure was $909904.0, 6.04% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $275004.0 at China SXT Pharmaceuticals, down from $909904.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $3.1 million in Q1 2023 and troughed at $84552.0 in Q3 2022.
  • A 5-year average of $760353.4 and a median of $291511.5 in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: surged 264.3% in 2023 and later tumbled 69.18% in 2024.
  • Year by year, Accumulated Expenses stood at $264903.0 in 2021, then crashed by 68.08% to $84552.0 in 2022, then surged by 264.3% to $308019.0 in 2023, then crashed by 57.81% to $129945.0 in 2024, then skyrocketed by 111.63% to $275004.0 in 2025.
  • Business Quant data shows Accumulated Expenses for SXTC at $275004.0 in Q3 2025, $909904.0 in Q1 2025, and $129945.0 in Q3 2024.